Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences

Posted on: 24 Aug 16

CAMBRIDGE, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will participate in two upcoming investor conferences:

  • Citi's 11th Annual Biotech Conference
    Panel: Gene Therapy: A New Era
    Wednesday, September 7, 2016 at 1:00 p.m. Eastern Time
    The Mandarin Oriental Hotel, Boston, MA

  • 2016 Wells Fargo Healthcare Conference
    Fireside Chat: Thursday, September 8, 2016 at 3:30 p.m. Eastern Time
    The Westin Boston Waterfront Hotel, Boston, MA

Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

About Dimension Therapeutics

Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.

For more information, please visit


Last updated on: 25/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.